Entropy Technologies LP Sells 1,297 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Entropy Technologies LP trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 43.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,683 shares of the biotechnology company's stock after selling 1,297 shares during the quarter. Entropy Technologies LP's holdings in United Therapeutics were worth $603,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Sei Investments Co. raised its position in United Therapeutics by 3.2% during the 1st quarter. Sei Investments Co. now owns 37,257 shares of the biotechnology company's stock worth $8,562,000 after purchasing an additional 1,149 shares during the last quarter. ProShare Advisors LLC boosted its holdings in United Therapeutics by 2.1% in the first quarter. ProShare Advisors LLC now owns 5,589 shares of the biotechnology company's stock valued at $1,284,000 after acquiring an additional 117 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in United Therapeutics by 2.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 48,197 shares of the biotechnology company's stock valued at $10,794,000 after purchasing an additional 1,200 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company's stock worth $5,901,000 after purchasing an additional 4,100 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of United Therapeutics by 1,973.9% in the 1st quarter. Intech Investment Management LLC now owns 19,412 shares of the biotechnology company's stock worth $4,459,000 after purchasing an additional 18,476 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR stock traded down $23.02 during trading hours on Friday, reaching $363.25. The company had a trading volume of 619,975 shares, compared to its average volume of 463,344. The company has a market cap of $16.22 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. The business has a fifty day simple moving average of $362.57 and a 200-day simple moving average of $326.65. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the business posted $5.38 EPS. The business's revenue was up 22.9% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 15,000 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total transaction of $6,021,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Monday, August 19th. The stock was sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. The trade was a 96.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 113,396 shares of company stock worth $42,175,418. Insiders own 11.90% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. Argus lifted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Bank of America lowered their target price on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.